Novo Nordisk Data Breach: Hackers Stole Drug Research and AI Models

Novo Nordisk, a Denmark-based pharmaceutical manufacturer, announced that it has experienced a data breach. The company claimed that hackers stole drug research, clinical trial data, and artificial intelligence models. The company is working with cybersecurity teams to determine the scope of the incident and has informed relevant regulatory authorities. The data breach may impact the company's research and development activities. Investors are assessing the potential impact of the data security incident on the company's market performance and stock prices. The company's statements provide information about its risk management strategies and future security measures. This development highlights the importance of data protection measures in the pharmaceutical industry. The company continues to strengthen its data security protocols. This is not an investment advice.

📊 NVO — Piyasa Yorumu

▼ down · 70%

Novo Nordisk has reported a cyberattack in which critical drug research data and AI models were stolen. Such a data breach could severely damage the company's intellectual property and competitive advantage, while also triggering regulatory scrutiny and potential lawsuits. Technical indicators already point to a weak position: the RSI is near the oversold zone at 43, the MACD is below the signal line, and the price is trading below both the 20-day and 50-day moving averages. The 1.58% decline in the last 24 hours indicates selling pressure even before the negative news. In the short term, the stock is expected to fall further due to this adverse development.

RSI 14

43.1

MACD

-0.19

24h Δ

-1.58%

Canlı Grafikler